Schoen

Schoen v. Eiger BioPharmaceuticals, Inc.

Good Law
United States District Court, Northern District of CaliforniaFebruary 3, 20233:22-cv-06985California1,340 words

Opinion

Trial Court Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA

RONALD A. SCHOEN,

Case No. 22-cv-06985-RS Plaintiff, 11 v. ORDER GRANTING SHANE SKINNER’S MOTION TO APPOINT

EIGER BIOPHARMACEUTICALS, INC., LEAD PLAINTIFF

et al.,

Defendants.

I. INTRODUCTION Three individuals—Shane Skinner, James Tomaiko, and George Fareed—filed cross- motions for appointment as lead plaintiff in this putative class action against Eiger Biopharmaceuticals, Inc. (“Eiger”) and related Defendants. For the reasons that follow, Skinner and Levi & Korsinsky, LLP are appointed lead plaintiff and lead counsel, respectively. II. BACKGROUND On November 8, 2022, Ronald A. Schoen filed a complaint on behalf of a purported class of similarly situated shareholders against Defendant Eiger, a biopharmaceutical company focusing on therapies for rare diseases; as well as individual Defendants David A. Cory, Eiger’s President 24 …

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.